Utama › Kanser Orofaring › Nebraska
Kajian klinikal Kanser Orofaring di Nebraska
5 kajian untuk Kanser Orofaring sedang mencari peserta di lokasi di Nebraska.
Bandar di Nebraska
Teks kajian rasmi (Bahasa Inggeris)
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Sep 2026 · NCT07195734BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Nebraska Medicine-Bellevue, Bellevue
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT05136196Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
- University of Nebraska Medical Center, Omaha
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 18 ke atas · Semua jantina · Dikemas kini 23 Sep 2026 · NCT06305676Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 29 Jul 2026 · NCT04198766Integrated Cancer Repository for Cancer Research
- Mary Lanning Healthcare, Morrison Cancer Center, Hastings
- Faith Regional Health Services, Carson Cancer Center, Norfolk
- Great Plains Regional Medical Center, North Platte
- dan 3 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.